Key result
Reperfusion therapy shows no significant 30-day mortality benefit in acute PE with right heart thrombi.
Why the study?
Right heart thrombi are associated with worse outcomes in pulmonary embolism, but the impact of reperfusion therapy on mortality is unclear.
Does reperfusion therapy reduce all-cause or PE-related mortality in patients with acute pulmonary embolism and right heart thrombi?
Observational (n=443)
Yes
Does reperfusion therapy reduce all-cause or PE-related mortality in patients with acute pulmonary embolism and right heart thrombi?
Reperfusion therapy was not associated with a significant reduction in mortality among patients with acute pulmonary embolism and right heart thrombi.
Answers are grounded in this paper and cite their sources.
Reperfusion therapy was not associated with lower mortality; leaves open its role pending randomized trials in this high-risk group.
Right heart thrombi portend worse outcomes in pulmonary embolism (PE). In propensity-matched analyses of patients from a large registry, reperfusion therapy was not associated with significantly reduced odds of all-cause or PE-related mortality.https://bit.ly/2WRLYnq
No takes yet. Share an insight, caveat, or question.
Bikdeli et al. (2020) conducted an observational in Acute pulmonary embolism and right heart thrombi (n=443). Reperfusion therapy vs. No reperfusion therapy was evaluated on 30-day PE-related mortality (OR 0.65, 95% CI 0.20-2.16, p=0.48). In patients with acute pulmonary embolism and right heart thrombi, reperfusion therapy was not associated with reduced odds of 30-day PE-related mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: